louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06355193: The Use of Isatidis Root and Forsythia Oral Liquid for the Treatment of Mild Cases of COVID-19: A Trial Clinical Study
Official title: The Use of Isatidis Root and Forsythia Oral Liquid for the Treatment of Mild Cases of COVID-19: A Trial Clinical Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Treatment of Mild Cases of COVID-19
Lead sponsor: Central South University
Sponsor class: OTHER
First posted: 2024-04-09
Enrollment: 253
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study has significant implications for research, as it provides a basis for further studies on the antiviral effects of LGLQ Oral Liquid, encouraging more extensive clinical studies in larger populations and diverse age groups to validate these findings. For medical practice, the findings suggest that LGLQ can be considered an alternative treatment option for mild cases of COVID-19, especially in managing symptoms like fatigue, potentially broadening the range of effective treatments available to healthcare practitioners. In terms of policy, the demonstrated efficacy of LGLQ could lead to its inclusion in treatment guidelines for COVID-19 and other viral infections, fostering a more integrated approach combining Western medicine and Traditional Chinese Medicine in the global fight against pandemics. The insights from this study might prompt health policymakers to reassess the potential of herbal formulations in managing and treating infectious diseases and consider them in the development of future healthcare strategies and policies.


Eligibility criteria: Inclusion Criteria:

* the diagnosis of SARS-Cov-2 infection confirmed by quantitative polymerase chain reaction (qPCR) test
* aged 18 years or older
* patients received more than 2 doses of SARS-Cov-2 vaccine
* asymptomatic or mild at the time of hospitalization

Exclusion Criteria:

* patients with malignant diseases, autoimmune diseases, liver and kidney diseases, blood diseases, neurological diseases, endocrine diseases and other serious diseases may affect the patient's participation in the trial or affect the results of the study
* pregnant women, lactating mothers; allergic conditions
* allergic to the known components of the drug
* patients vaccinated with vaccines less than 1 shot
* Patient does not agree to participate in this study

Primary outcomes:
measure: Treatment and symptomatic improvement effects of LGLQ
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Changde
country: China
facility: Changde Hospital
state: Hunan
Study officials:
References:
Clinical trial NCT04230993: Efficacy of Two Nasal Products for Decongestion and Mucus Fluidification
Official title: Clinical Evaluation of the Efficacy of Two Nasal Products for Decongestion and Mucus Fluidification
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Rhinitis
Lead sponsor: YSLab
Sponsor class: INDUSTRY
First posted: 2020-01-18
Enrollment: 210
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective is to compare the effect of nasal washing on nasal discharge and nasal congestion during treatment after 3 days of use.

Detailed description: The main endpoint is a symptom score derived from the Jackson scale: sum of 2 items relating to runny nose and nasal congestion (stuffy nose), with ratings of 0 to 3 for each (0: absent ; 1: mild; 2: moderate; 3: severe).

Eligibility criteria: Inclusion Criteria:

* Person with an upper respiratory condition (cold, rhinitis, nasopharyngitis ...) with symptoms of nasal congestion and intense runny nose moderate to severe (Jackson derived score ≥ 4)
* Ability of the patient (for adults) or their legal representative (for children) to follow the guidelines of the medical device
* have given their written informed consent

Exclusion Criteria:

* Patient with no cold symptoms, including no nasal congestion (chronic dry rhinitis...)
* Patient under treatment with cortisone derivative, mucolytic, or medication containing pseudoephedrine or related product acting on nasal congestion or having used such a product in the 3 days before inclusion
* Patient who used a nasal wash product in the 3 days before inclusion
* Patient allergic to seafood, or to any of the components of the products under study
* Vulnerable patient whose inclusion is not justified by the research objectives: woman pregnant, parturient, psychiatric patient, or adult subject to legal protection
* Patient participating or having participated in any other clinical study in the 30 days before the study.

Primary outcomes:
measure: Effect of nasal washing with a hypertonic seawater solution Nose hygiene).
timeFrame: 3 days
Secondary outcomes:
measure: Symptom score
timeFrame: 7 days
measure: Presence or absence of fluid mucus
timeFrame: 7 days
measure: Global Clinical Impression Scale
timeFrame: between day 3 and day 7
measure: Global Patient Impression Scale
timeFrame: between day 3 and day 7
measure: Use of medical device
timeFrame: 7 days
measure: Safety of medical device
timeFrame: 7 days
measure: Likert scale
timeFrame: 7 days
measure: Number of concomitant treatment
timeFrame: 7 days
Other outcomes:
Locations:
city: Oignies
country: France
facility: Medical office
Study officials:
affiliation: Coordinator of the study
name: Alain BOYE, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03603093: A Multicenter Survey of the Indications for Esophagogastroduodenoscopy (EGD)
Official title: Children's Hospital of Fudan University
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Digestive System Abnormalities
Endoscopy
Keywords: Esophagogastroduodenoscopy
Paediatric
Lead sponsor: Children's Hospital of Fudan University
Sponsor class: OTHER
Collaborators: name: Hunan Children's Hospital
name: Wuhan Children's Hospitall
name: Xiamen Children's Hospital
name: Henan Provincial People's Hospital
First posted: 2018-07-27
Enrollment: 2287
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All of the patients need esophagogastroduodenoscopic procedures

Brief summary: Esophagogastroduodenoscopy (EGD) become more and more common in diagnosing gastroenterology diseases. The investigators want to find which symptoms can support for positive endoscopic findings through this multicenter study.

Detailed description: Esophagogastroduodenoscopy (EGD) become more and more common in diagnosing gastroenterology diseases. And there are indications for EGD. Here, investigators want to find which symptoms can strongly support for positive endoscopy findings. So, investigators design the study to record the symptoms in detail and diagnosis, and then analysis symptoms and the rate of endoscopic findings.

Eligibility criteria: Inclusion Criteria:

* All of the patients need esophagogastroduodenoscopic procedures

Exclusion Criteria:

* Patients whose parents reject to provide information for study

Primary outcomes:
measure: Quantities of every indications for esophagogastroduodenoscopic procedures collected from questionaire finished by clinical doctor
timeFrame: from August 15th to October 15th in 2018
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Children's hospital of Fudan Universtity
Study officials:
affiliation: Children's Hospital of Fudan University
name: Ying Huang, doctor
role: STUDY_DIRECTOR
References:
citation: Wang S, Qiu X, Chen J, Mei H, Yan H, You J, Huang Y. Pediatric esophagogastroduodenoscopy in china: indications, diagnostic yield, and factors associated with findings. BMC Pediatr. 2022 Sep 2;22(1):522. doi: 10.1186/s12887-022-03558-x.
Clinical trial NCT05173493: The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
Official title: The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Helicobacter Pylori Infection
Keywords: Helicobacter pylori
Re-eradication time
Remedial treatment
Lead sponsor: Shandong University
Sponsor class: OTHER
Collaborators: name: Taian City Central Hospital
name: Dezhou People's Hospital
name: Weifang Medical University
name: The Affiliated Hospital of Qingdao University
name: Shengli Oilfield Hospital
First posted: 2021-12-30
Enrollment: 670
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The patients in Shandong province,aged between 18 and 70 years old, with positive H. pylori infection that was eradicated by previous therapies but failed are included.

Brief summary: The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

Detailed description: Helicobacter pylori (HP) infection is a common global infectious disease, which is an important cause of chronic gastritis, peptic ulcer and gastric cancer. At present, due to the non-standard Helicobacter pylori eradication program in clinical work, poor patient compliance and other reasons, the phenomenon of HP eradication treatment failure is more and more common. However, there is still no conclusion on the most appropriate time for remedial treatment inpatients with Hp eradication failure.

Eligibility criteria: Inclusion Criteria:

* Patients aged 18-70 with H. pylori infection.
* Patients with previous Helicobacter pylori eradication.

Exclusion Criteria:

* Patients treated with H2-receptor antagonist, PPI, bismuth and antibioticsin the previous 4 weeks.
* Patients with gastrectomy, acute GI bleeding and advanced gastric cancer.
* Patients with known or suspected allergy to study medications.
* Currently pregnant or lactating.
* Inability to provide informed consent and other situations that couldinterfere with the examination or therapeutic protocol.

Primary outcomes:
measure: The most suitable re-eradication time
timeFrame: 6 months
Secondary outcomes:
measure: Eradication rates in three groups
timeFrame: 6months
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu Hospital of Shandong University
state: Shandong
Study officials:
affiliation: Qilu Hospital of Shandong University
name: Xiuli Zuo
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01910493: Evaluation of the Impact of Mobile Phone Messages on ART and PMTCT Adherence in Mozambique
Official title: Evaluation of the Impact of Mobile Phone Messages on ART and PMTCT Adherence in Mozambique: A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV-positive
Keywords: mhealth
mobile health
SMS
SMS reminders
ART retention in care
PMTCT
PMTCT cascade
retention in care
Lead sponsor: Absolute Return for Kids
Sponsor class: OTHER
Collaborators: name: Vodacom
name: United States Agency for International Development (USAID)
name: Department for International Development, United Kingdom
First posted: 2013-07-29
Enrollment: 1352
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Mobile phone SMS are increasingly used to promote positive health behaviour with an aim to improve health outcomes. However, robust data on the efficacy of SMS on health seeking behaviour and patient outcomes in resource-limited settings is sparse. The SMSaude study aims to assess whether regular SMS-reminders improve retention on antiretroviral therapy (ART) and prevention of mother to child transmission of HIV (PMTCT) programmes in Mozambique.

Detailed description: SMSaúde is a multisite randomised clinical trial of HIV-infected adults on ART and HIV-infected pregnant women in six clinics in Maputo Province, Mozambique. Eligibility criteria include: currently residing in the province; no plans to move for 12+ months; have own cell-phone; literate; 8-28 weeks pregnant (PMTCT cohort); on first line ART and on ART for \>15 days (ART cohort). Patients were interviewed for eligibility, and then randomized (1:1). SMS reminders are sent to the intervention group using software that picks up the patient's next appointment from the electronic patient database. Primary outcomes tested were improved retention in ART care and uptake of all PMTCT services.

Eligibility criteria: Inclusion Criteria:

* On ART for \>15 days (for ART only)
* Live in province and plan to stay for 12+ months
* Have cell phone
* Literate

For PMTCT (in addition to above criteria):

- pregnant between 8-28 weeks

Exclusion Criteria:

-

Primary outcomes:
measure: Retention in ART care
timeFrame: 12 months
Secondary outcomes:
measure: Retention in PMTCT care
timeFrame: until 8 weeks post partum
Other outcomes:
Locations:
city: Matola, Xinavane, Machava and Namaacha
country: Mozambique
facility: 6 Health Facilities
state: Maputo
Study officials:
affiliation: University of Eduardo Mondlane
name: Cesar de Palha, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05356793: The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
Official title: A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Infectious Conjunctivitis (Disorder)
Keywords: Conjunctivitis
Eye
Lead sponsor: Sacsh
Sponsor class: INDUSTRY
First posted: 2022-05-02
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.

Detailed description: This is a Phase II single-center, double-masked, placebo controlled, randomized study of SCH1 for the treatment of infectious conjunctivitis. Approximately 30 subjects will be enrolled, who will be randomized in a 1:1 ratio between SCH1and placebo. Subjects will be assessed at day 1, day 3, and day 5 for efficacy and safety.

Eligibility criteria: Inclusion Criteria:

* Conjunctivitis (as defined below) within 72 hours of initial ocular symptoms.
* At least 18 years of age.
* Subjects capable of understanding the purpose and risks of the study, and able to give informed consent.
* Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis- 1) bulbar conjunctival injection and 2) conjunctival discharge/exudates.
* A three-point rating scale (0=absent, 1=mild, 2=moderate, 3=severe) will be employed to grade conjunctival discharge/exudates.
* All patients will require a rating of 1(mild) or greater for conjunctival discharge/exudates.
* Patients will require a rating of 1 (mild) for bulbar conjunctival injection.

Exclusion Criteria:

* Conjunctivitis greater than 72 hours after initial ocular symptoms
* Corneal ulcer, endophthalmitis, or any other confounding infection of the eye
* Patients taking topical anti-inflammatory medications on a chronic basis
* Known steroid glaucoma responders
* Active herpes ocular infection
* Pregnant women
* Known allergy to chlorhexidine

Primary outcomes:
measure: Number of Participants With Clinical Resolution Among Who Received SCH1 or Placebo on Day 5
timeFrame: Day 5
Secondary outcomes:
Other outcomes:
Locations:
city: Jackson Heights
country: United States
facility: Jacqueline Dauhajre, MD
state: New York
Study officials:
affiliation: Sacsh
name: David Ritterband, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03287193: Identification of the Molecular And/or Pathophysiological Bases of Developmental Diseases
Official title: Identification of the Molecular And/or Pathophysiological Bases of Developmental Diseases
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Developmental Anomalies
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2017-09-19
Enrollment: 850
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients followed at the Centre de Référence Anomalies du Développement du CHU de Dijon

Brief summary: Developmental diseases include more than 3000 diseases and can associate organ malformation, dysmorphism, development disorders and/or intellectual deficiency. Even though the considerable effort in the search for genes in the last 20 years has led to the identification of thousands of genes associated with Mendelian diseases, half of the individuals with severe development anomalies remain without a genetic diagnosis. It is important to pursue the ambition to contribute to the goal fixed by Europe, namely the identification of the large majority of genes responsible for rare diseases with development anomalies, and to be able to provide genetic counselling to patients and their families. In the past, scientific research to discover genes required a large number of families and individuals and was slow and expensive to carry out. Today, this approach has been facilitated by next generation sequencing.


Eligibility criteria: Inclusion Criteria:

* Patients (foetus/children and adults) with development anomalies whose molecular bases are unknown, or for which the pathophysiological mechanism is poorly understood
* Consent of the patient or his/her legal representative
* Suitable level of understanding

Exclusion Criteria:

* Patients without national health insurance cover

Primary outcomes:
measure: Number of new genes identified.
timeFrame: through study completion, an average of 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: Chu Dijon Bourogne
Study officials:
References:
Clinical trial NCT00620893: Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Dry Eye Syndromes
Keywords: Dry eye signs and symptoms
refractive regression
Lead sponsor: Bp Consulting, Inc
Sponsor class: NETWORK
First posted: 2008-02-22
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate and compare 2 artificial tears in their ability to reduce post LASIK dry eye signs and symptoms. The secondary endpoint of this study is to evaluate refractive regression in these patients. The 'Refractive Outcome' data point will be defined as the difference between the post-op spherical equivalent (SE) and the pre-op targeted SE.


Eligibility criteria: Inclusion Criteria:

* Patients ranging from normal to mild dry eye per physician assessment
* BCVA of 20/20
* Moderate to high myopia (-3 D to -10D of sphere)
* Patients who are scheduled to under go myopic bilateral LASIK with VISX laser

Exclusion Criteria:

* Patients currently using topical cyclosporine
* Patients currently using Systane
* Patients currently using an oil-based artificial tear such as Soothe or Endura
* Any post-op epithelial defects or flap complications requiring further procedures (relifting, scraping, stretching etc.)
* DLK greater than stage 1 or infectious keratitis post-operatively
* Any uncontrolled systemic disease that may confound the results of this trial (Diabetes, Lupus, Rheumatoid Arthritis etc.)
* Anisometropia greater than 1D

Primary outcomes:
measure: dry eye signs
timeFrame: 9 months
Secondary outcomes:
measure: refractive regression
timeFrame: 9 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medical Center
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Christopher Starr, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05490693: The Effect of Virtual Reality Glasses Used During Burn Dressing in Children on Pain, Anxiety and Fear
Official title: The Effect of Virtual Reality Glasses Used During Burn Dressing in Children on Pain, Anxiety and Fear
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Randomized
Lead sponsor: Ondokuz Mayıs University
Sponsor class: OTHER
First posted: 2022-08-08
Enrollment: 1
Sex: ALL
Minimum age (years): 5
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: In order to determine the number of samples, power analysis was performed using the G\*power program. The effect size coefficient was calculated by using the Newcastle satisfaction scale averages in source 1 (thesis), and the effect size = 0.76, and it was decided to recruit at least 26 people in each group in order to obtain 80% power at the ɑ=0.05 level, a total of 52 people in the two groups.

Brief summary: This work; It was planned as a randomized controlled study to determine the effect of watching cartoons with virtual reality glasses during burn dressing of children aged 5-10 years who applied to the Training and Research Hospital Burn Unit Polyclinic on the feeling of pain, anxiety and fear in children.

Detailed description: The study will be applied to children in the 5-10 group who will undergo burn dressing. During the dressing, children will be watched cartoons with virtual reality glasses and pain, anxiety and fear will be looked at before and after the dressing. The children in the control group will be given routine applications of the clinic.

Eligibility criteria: Inclusion Criteria:

* The child and family agree to participate in the research,
* The child does not have a disease that causes chronic pain,
* The child is between the ages of 5-10,
* 1st and 2nd degree burns of less than 10% of the body surface area of the child,
* Local burn, no facial burn
* The child has no mental or neurological disability
* Failure to intervene in the child with general anesthesia
* The child has no eye problems

Exclusion Criteria:

* Child and family refusal to participate in the study
* 3rd and 4th degree burns of more than 10% of the body surface area of the child,
* The child is less than 5 years old and over 10 years old
* The child has a mental or neurological disability
* Intervention of the child with general anesthesia
* The child has an eye problem

Primary outcomes:
measure: pain, anxiety, fear scores,
timeFrame: July 2022-October 2022
Secondary outcomes:
Other outcomes:
Locations:
city: Samsun
country: Turkey
facility: Omü
state: İlkadım
city: Samsun
country: Turkey
facility: 19May University
Study officials:
References: